GMP compliance differs between FDA and EMA standards primarily in regulatory framework, inspection authority, documentation expectations, and specific technical requirements. While both agencies share the same core goal of ensuring product safety, efficacy, and quality, the practical rules they enforce reflect different legislative traditions and enforcement philosophies. Companies seeking approval in both markets need to understand where these frameworks align and where they genuinely diverge.
What specific GMP requirements does the FDA enforce that the EMA does not?
The FDA enforces several GMP requirements that have no direct equivalent in EU regulations. The most significant is the FDA’s Current Good Manufacturing Practice (cGMP) framework under 21 CFR Parts 210 and 211 for drugs, which includes explicit requirements around process validation terminology, annual product reviews (now called Product Quality Reviews under EU GMP), and specific equipment qualification language. The FDA also places stronger regulatory weight on out-of-specification (OOS) investigation procedures, with formal guidance that effectively makes written OOS investigations a binding expectation rather than a recommendation.
Another area where the FDA goes further is in its requirements for laboratory controls under 21 CFR Part 211, Subpart I. The FDA expects more prescriptive documentation of laboratory testing procedures and places particular emphasis on data integrity at the instrument level. Additionally, the FDA’s Consent Decree framework and warning letter enforcement create compliance obligations that have no direct counterpart in the EU’s GMP inspection system, which operates through national competent authorities coordinated by the EMA.
How do FDA and EMA GMP inspections differ in practice?
FDA and EMA GMP inspections differ in structure, frequency, and enforcement outcomes. The FDA conducts inspections directly through its own investigators, primarily from the Office of Pharmaceutical Quality, and can issue Form 483 observations followed by Warning Letters or Import Alerts. EMA inspections are carried out by national competent authorities within EU member states, with the EMA coordinating mutual recognition and overseeing inspections for centrally authorized products.
FDA inspection characteristics
FDA inspections tend to be unannounced for domestic facilities and follow a risk-based scheduling model. Investigators use a systems-based inspection approach covering quality systems, facilities, laboratory controls, production, packaging, and materials. A critical finding can lead directly to import restrictions, making the commercial stakes of each inspection very high. The FDA also maintains a public database of inspection outcomes, adding a transparency dimension that affects company reputation.
EMA inspection characteristics
EU GMP inspections are typically pre-announced and conducted by teams from the relevant national competent authority. For centrally authorized products, the EMA’s GMP/GDP Inspectors Working Group coordinates cross-border inspections. Outcomes are recorded in the EudraGMDP database, and a non-compliant finding results in the withdrawal or suspension of the GMP certificate. The EU system places strong emphasis on the Qualified Person (QP) as a legal accountability mechanism, a role that has no direct FDA equivalent.
What are the main documentation differences between FDA and EMA GMP standards?
The main documentation differences between FDA and EMA GMP standards lie in structure, terminology, and the role of specific documents. EU GMP relies heavily on a hierarchical documentation system described in Annex 15 and Part I of the EU GMP Guidelines, with explicit requirements for Site Master Files (SMFs), which the FDA does not formally require in the same way. The EU also mandates a formal Product Quality Review (PQR) structure that, while similar to the FDA’s Annual Product Review concept, has distinct formatting and content expectations.
The FDA’s documentation requirements under 21 CFR Part 211 are more prescriptive about specific record types, including batch production records, laboratory records, and distribution records, with defined retention periods. The EU GMP framework, updated through EudraLex Volume 4, tends to be principles-based, giving manufacturers more flexibility in how they structure documentation, but requiring that the chosen system be fully validated and consistently applied. Data integrity expectations have converged significantly in recent years, with both agencies now aligned on ALCOA+ principles, but enforcement emphasis and audit trail requirements can still differ in practice. Our team at Starodub regularly helps companies navigate these documentation differences — you can learn more about our regulatory and compliance services to see how we support clients across both frameworks.
How does GMP compliance for biologics differ between the FDA and EMA?
GMP compliance for biologics differs between the FDA and EMA in regulatory framework, technical guidance, and oversight structure. The FDA regulates biologics under the Public Health Service Act and 21 CFR Parts 600 to 680, in addition to standard drug cGMP requirements. The EMA regulates biologics primarily through EU GMP Annex 2, which covers the manufacture of biological active substances and medicinal products for human use, alongside ICH guidelines that both agencies have adopted.
One of the most practical differences is in how each agency handles comparability exercises following manufacturing changes. The FDA’s guidance on comparability tends to expect more extensive data packages and may require prior approval for certain changes, while the EU system uses a variations classification framework that can allow some comparability changes to be implemented with notification rather than approval. For advanced therapy medicinal products (ATMPs), the EMA has a dedicated regulatory pathway and specific GMP requirements under Regulation (EC) No 1394/2007, which creates compliance obligations that differ substantially from the FDA’s approach to cell and gene therapy products.
Should a company align its GMP system to FDA or EMA standards first?
A company should generally align its GMP system to the more stringent of the two frameworks first, then adapt for the other market. In practice, this often means building to FDA cGMP standards as the baseline, since FDA requirements tend to be more prescriptive and enforcement consequences more immediate. A system built to satisfy FDA expectations can typically be adapted to meet EU GMP requirements with targeted additions, particularly around the Site Master File, Qualified Person accountability, and the variations framework.
However, the right starting point depends on the company’s primary market, product type, and development stage. For a European company developing a biologic for EU approval first, building to EU GMP standards and Annex 2 requirements makes practical sense, with a structured gap analysis against FDA cGMP conducted before US market entry. Companies targeting simultaneous approval in both markets should conduct a dual-framework gap analysis early in development to avoid costly remediation later. Mutual recognition agreements between the EU and US, which cover GMP inspections for human medicines, can reduce duplicated inspection burden once both certifications are in place. If you would like to understand how Starodub approaches these challenges, visit our company page for background on our experience and expertise.
What happens when a product meets EMA GMP standards but not FDA requirements?
When a product meets EMA GMP standards but not FDA requirements, the FDA can refuse to approve the marketing application, issue an Import Alert, or place the manufacturing facility on an import hold. EMA GMP certification does not automatically satisfy FDA requirements, even where mutual recognition agreements exist, because those agreements cover inspection reliance rather than full regulatory equivalence. The FDA retains the right to conduct its own inspections and apply its own standards.
Common gaps that create this situation include differences in OOS investigation documentation, data integrity audit trail requirements, process validation terminology and stage definitions, and laboratory control records. A facility that has passed an EU GMP inspection may still receive FDA Form 483 observations in these areas. The practical solution is to conduct a targeted FDA cGMP gap assessment against the current EU-compliant quality system, prioritize findings by regulatory risk, and remediate before an FDA pre-approval inspection is triggered by a US marketing application.
How Starodub helps with GMP compliance across FDA and EMA standards
Navigating the differences between FDA and EMA GMP requirements is one of the most technically demanding challenges in bringing a product to market in both regions. We work with biopharmaceutical and medical device companies to make that process manageable and efficient. Our regulatory affairs professionals bring hands-on experience with both frameworks, helping companies avoid the costly remediation that comes from discovering compliance gaps late in development.
Here is how we support GMP compliance across both regulatory systems:
- Dual-framework gap analysis: We assess your existing quality system against both FDA cGMP and EU GMP requirements, identifying where the two frameworks diverge and prioritizing remediation by regulatory risk.
- Documentation strategy: We help structure your GMP documentation to satisfy both EU GMP’s principles-based expectations and FDA’s more prescriptive record requirements, including Site Master Files, batch records, and OOS investigation procedures.
- Biologics and ATMP compliance: We provide specialist support for biologics and advanced therapy medicinal products, where GMP requirements under FDA 21 CFR Parts 600 to 680 and EU GMP Annex 2 create distinct and complex obligations.
- Inspection readiness: We prepare your team for both FDA pre-approval inspections and EU GMP audits, covering systems-based inspection approaches and the documentation expectations of each agency.
- Ongoing compliance support: Through our Quality, Compliance and Operational Improvements division, we help companies build sustainable GMP systems that hold up across regulatory cycles and manufacturing changes.
If your company is preparing for dual-market approval or working through a GMP gap identified during an inspection, get in touch with us to discuss how we can support your compliance strategy.
Related Articles
- What happens during an FDA GMP compliance inspection?
- What is the difference between GMP compliance and GMP certification?
- What are the benefits of having a regulatory affairs strategy?
- CE Marking for Medical Devices: A Step-by-Step Guide
- ATMP Regulation in Europe: What Developers of Cell and Gene Therapies Need to Know
This content was generated with the help of AI and it may contain mistakes
